CPT code 81540 designates a molecular diagnostic service that combines technical RT–PCR testing of 92 genes on tumor tissue with an algorithmic analysis to predict a tumor’s main cancer type and subtype. This code captures both the laboratory analytic component and the computational interpretation that yields a probabilistic cancer-type report, making it relevant for precision oncology workups and cases where tissue-based molecular classification informs diagnostic clarity.

Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 81540 represents, why it matters for laboratory and oncology providers, and the typical clinical and laboratory contexts in which it is used.

The publication summarizes expected benchmarks and adoption considerations, clarifies clinical context for ordering and reporting such tests, and highlights where policy updates and payer coverage practices can influence access to algorithm-driven tumor profiling. The content is intended as a national-level reference for health plan administrators, laboratory directors, and oncology practice managers seeking a clear description of the service and the key issues surrounding reimbursement and clinical utility.